Inhibikase Therapeutics IKT reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Inhibikase Therapeutics beat estimated earnings by 5.26%, reporting an EPS of $-0.18 versus an estimate of $-0.19.
Revenue was down $1.36 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 1.63% increase in the share price the next day.
Here's a look at Inhibikase Therapeutics's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.17 | -0.14 | -0.38 |
| EPS Actual | -0.18 | -0.20 | -0.18 | -0.22 |
| Revenue Estimate | 300K | 300K | 328K | 300K |
| Revenue Actual | 46K | 1.94M | 328K | 1.36M |
To track all earnings releases for Inhibikase Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
